The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Hospira, Inc., a Pfizer company, is recalling the below referenced lots of **Buprenorphine Hydrochloride Injection** and **Labetalol Hydrochloride Injection, USP**. Pfizer initiated this recall due to the potential for incomplete crimp seals. Pfizer completed a Health Hazard Assessment, which concluded that in the event that impacted products are administered to a patient, there is a potential of an increased risk of lack of therapeutic effect, bloodstream infections, septicemia, respiratory distress, stroke, and hypersensitivity reactions.

To date, Pfizer has not received reports of any relevant adverse events associated with this issue for these lots.

Buprenorphine Hydrochloride Injection - CIII

Carton NDC	Cartridge NDC	Lot Number	Expiration Date	Concentration	Configuration/Count
0409-2012-32	0409-2012-03	HJ3965	2024/09	0.3 mg base/mL	Carton of 10 x 1 mL Carpuject™ Single- dose Cartridge/tube units with Luer Lock
		HJ8546	2024/10		

Labetalol Hydrochloride Injection, USP

Bundle NDC	Carton/ Cartridge NDC	Lot Number	Expiration Date	Concentration	Configuration/Count
0409-2339-34	0409-2339-24	HJ7566	2025/05	20 mg/4 mL (5 mg/mL)	Bundle containing 10 Cartons of 1 x 4 mL Carpuject™ Single-dose Cartridge units with Luer Lock
		HN8747	2025/09		
		HN8749	2025/09		